From next-generation targeted therapies to innovations in cell therapy, progress across hematologic malignancies is accelerating—and with it, new research questions are emerging. Join us for a live conversation with oncology industry experts as they explore how rapid therapeutic advances in blood cancers are transforming both the scientific landscape and patient care. In this recorded webinar, our panel discussed:
- How these scientific and clinical breakthroughs are reshaping evidence needs across the product lifecycle
- Why high-quality, longitudinal real-world data has become essential for understanding sequencing, long-term safety, and real-world outcomes across diverse patient populations
- How multidisciplinary teams are using real-world evidence across the therapeutic development lifecycle to ultimately support the delivery of therapies that improve the lives of patients with hematologic malignancies
